YAP1 Overexpression

CI-VAR-00003164Explore in graph →CIViC 869

Curated evidence

Evidence by cancer (3 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–3 of 3 evidence items across 1 cancer context on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Malignant Esophageal Neoplasm3
YAP1 Overexpression	Docetaxel + FluorouracilSubstitutes	Predictive	D	Supports Resistance	2	submitted	EID1982 YAP1 up-regulation of EGFR plays an important role in conferring therapy resistance to 5-FU or docetaxel in esophageal cancer (EC) cells. Inhibitor of YAP1, Verteporfin, can overcome the acquired chem… (full text at CIViC) PMID 25739674 · Song et al., 2015 · Open in CIViC	civic
YAP1 Overexpression	Verteporfin	Predictive	D	Supports Sensitivity Response	2	submitted	EID1983 YAP1 up-regulation of EGFR plays an important role in conferring therapy resistance to 5-FU or docetaxel in esophageal cancer (EC) cells. Inhibitor of YAP1, Verteporfin, can overcome the acquired chem… (full text at CIViC) PMID 25739674 · Song et al., 2015 ·

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.